Volume 5, Issue 2 (6-2013)                   IJDO 2013, 5(2): 88-90 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Dhore R, Dhore A, Wasnik V, Jadhav N. Effect of Bromocriptine Mesylate as Add-On Therapy in Obese Type 2 Diabetes Mellitus Patients. IJDO 2013; 5 (2) :88-90
URL: http://ijdo.ssu.ac.ir/article-1-139-en.html
Effect of Bromocriptine Mesylate as Add-On Therapy in Obese Type 2 Diabetes Mellitus Patients
Rajendra Dhore , Akshay Dhore , Vinod Wasnik * , Nilesh Jadhav
MBBS, M.D. (PSM) Associate Professor, Department of Community Medicine. Dr. Panjabrao Deshmukh .Medical College, Amravati Maharashtra ,India
Abstract:   (30494 Views)
Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese type 2 diabetic patients.
Keywords: T2DM, Bromocriptine mesylate, HbA1c
Full-Text [PDF 98 kb]   (1860 Downloads)    
Type of Study: Research | Subject: Special
Received: 2014/03/15 | Accepted: 2014/03/15 | Published: 2014/03/15
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb